Phase 3 Ovarian Cancer Trial, Recruiting NCT04063527 Sponsor: Japanese Gynecologic Oncology Group Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT04063527
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with epithelial ovarian cancer, confirmed by a laboratory examination of tissue
  • People whose cancer has been classified at a specific stage: FIGO Stage Ia or Ib (Grade 2 or 3, or a type called clear cell carcinoma), or FIGO Stage Ic(b) (any grade or type) (confirm with trial site if stage is unclear)
  • People whose cancer stage was confirmed through a thorough surgical procedure called comprehensive staging or restaging surgery
  • People who had a full staging surgery that included removal of the uterus, both ovaries and fallopian tubes, and the omentum (a layer of tissue in the abdomen), along with fluid sampling, tissue biopsies from the lining of the abdomen, and removal of lymph nodes in the back of the abdomen — with some exceptions allowed if certain steps were not fully completed for documented reasons
  • People aged 20 or older
  • People with a general health and activity level rated at 0 or 1 on a standard scale used by doctors (meaning fully active or able to carry out light activity)
  • People who have not yet received any treatment for the cancer after surgery
  • People for whom the first study treatment can begin within 8 weeks of the staging surgery
  • People whose organs (such as kidneys, liver, and bone marrow) are functioning at an acceptable level
  • People who have given written informed consent to participate

Who may not be able to join:

  • People whose cancer is classified as FIGO Stage Ic(a), Ic(1), or Ic(2)
  • People whose tumour contains sarcoma elements (a particular type of cancer cell)
  • People who show signs of interstitial pneumonia (a type of lung inflammation) or pulmonary fibrosis (scarring of the lungs) on chest X-ray or CT scan
  • People who have serious other medical conditions
  • People who have an active infection at the time of joining
  • People who have a condition where the bowel is not moving properly, or a bowel blockage
  • People who currently have another cancer, or who had a different cancer within the past 5 years
  • People who have previously received chemotherapy or radiation therapy
  • People with a history of serious allergic reactions to medications
  • People who have moderate to severe nerve damage affecting movement or sensation (graded 2, 3, or 4 on a standard medical scale)
  • People who have previously had an allergic reaction to polyoxyethylated or hydrogenated castor oil (substances used in some medications)
  • People who test positive for a specific marker of Hepatitis B infection (HBsAg), or who have certain levels of Hepatitis B virus detected in their blood alongside other Hepatitis B markers
  • People who the treating doctor considers unsuitable for the trial for any safety reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hiroshi Tanabe, M.D., National Cancer Center Hospital East

Phone: 81-4-7133-1111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Japanese Gynecologic Oncology Group
Registry
ClinicalTrials.gov
Start date
20 July 2012
Est. completion
1 October 2029

Where this trial is recruiting

🇯🇵 Japan 🇰🇷 South Korea

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov